| Original language | English |
|---|---|
| Pages (from-to) | 623-627 |
| Number of pages | 5 |
| Journal | British journal of haematology |
| Volume | 185 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2019 |
Keywords
- FLT3
- acute leukaemia
- midostaurin
- paediatric
- relapsed/refractory
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: British journal of haematology, Vol. 185, No. 3, 05.2019, p. 623-627.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
AU - Zwaan, C. Michel
AU - Söderhäll, Stefan
AU - Brethon, Benoit
AU - Luciani, Matteo
AU - Rizzari, Carmelo
AU - Stam, Ronald W.
AU - Besse, Emmanuelle
AU - Dutreix, Catherine
AU - Fagioli, Franca
AU - Ho, Phoenix A.
AU - Dufour, Carlo
AU - Pieters, Rob
N1 - Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children's Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Hôpital Universitaire Robert-Debré, Paris, France; IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children's Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luján, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation. Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children’s Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Hôpital Universitaire Robert-Debré, Paris, France; IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Cittàdella Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children’s Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luján, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation.
PY - 2019/5
Y1 - 2019/5
KW - FLT3
KW - acute leukaemia
KW - midostaurin
KW - paediatric
KW - relapsed/refractory
UR - https://www.scopus.com/pages/publications/85053413507
U2 - 10.1111/bjh.15593
DO - 10.1111/bjh.15593
M3 - Letter
C2 - 30203832
AN - SCOPUS:85053413507
SN - 0007-1048
VL - 185
SP - 623
EP - 627
JO - British journal of haematology
JF - British journal of haematology
IS - 3
ER -